COMbination of Bipolar Androgen Therapy and Nivolumab
Status:
Active, not recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
Single arm, multicenter, open-label Phase II study of the effects of parenteral testosterone
in combination with nivolumab in men with metastatic castration-resistant prostate cancer who
previously progressed on at least one novel androgen-receptor targeted therapy (i.e.
Abiraterone acetate, Enzalutamide). Up to one taxane agent is permitted.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins